ArticleDigestive disease interventions2025
Current Considerations in Nonoperative Surveillance of Intraductal Papillary Mucinous Neoplasms.
Article in Digestive disease interventions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas: History, Myths, and Realities Between Past and Future.Medical sciences (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Intraductal papillary mucinous neoplasms (IPMNs) account for the majority of incidentally found pancreatic cystic neoplasms. There are three general subtypes: main-duct (MD-IPMN), branch-duct (BD-IPMN), and mixed-type (MT-IPMN) which all carry varying degrees of malignant potential. The malignant risk of IPMN involving the main pancreatic duct ranges from 40 to 80% for both MD-IPMN and MT-IPMN, while the malignancy risk for BD-IPMN is more variable but considered to be much lower. The management of BD-IPMN is typically non-operative surveillance and remains a topic of debate. In this overview, we discuss the current controversies in management of BD-IPMN such as comparison of surveillance strategies based on consensus guidelines, perceived weight of various worrisome features (WF) and/or high-risk stigmata (HRS), molecular analyses, multifocality, cost effectiveness strategies, and high patient-risk features. This overview should provide a glimpse into the current state and controversies in the care of patients with BD-IPMN.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.